tacrolimus and Obesity--Morbid

tacrolimus has been researched along with Obesity--Morbid* in 3 studies

Other Studies

3 other study(ies) available for tacrolimus and Obesity--Morbid

ArticleYear
Prospective study of the changes in pharmacokinetics of immunosuppressive medications after laparoscopic sleeve gastrectomy.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2020, Volume: 20, Issue:2

    Laparoscopic sleeve gastrectomy induces weight loss via the creation of a restrictive gastric tube for early satiety and is associated with an accelerated gastric transit time. A prospective, single-dose pharmacokinetic study was performed, prior to and after laparoscopic sleeve gastrectomy, for tacrolimus, extended-release tacrolimus, mycophenolate mofetil, and enteric-coated mycophenolate sodium. The study included 12 morbidly obese patients in chronic renal failure. The median decrease in body mass index was 8.8 kg/m

    Topics: Female; Gastrectomy; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Laparoscopy; Male; Middle Aged; Mycophenolic Acid; Obesity, Morbid; Prospective Studies; Tacrolimus

2020
Meralgia paresthetica successfully treated with topical 0.1% tacrolimus: a case report.
    International journal of dermatology, 2016, Volume: 55, Issue:1

    Topics: Administration, Topical; Bariatric Surgery; Drug Administration Schedule; Female; Femoral Neuropathy; Follow-Up Studies; Humans; Hypertension; Middle Aged; Nerve Compression Syndromes; Obesity, Morbid; Pain; Postoperative Period; Pruritus; Tacrolimus; Treatment Outcome

2016
Change in oral absorption of tacrolimus in a liver transplant recipient after reversal of jejunoileal bypass: case report.
    Transplantation proceedings, 2005, Volume: 37, Issue:7

    Jejunoileal bypass (JIB) was, at one time, a popular surgical technique for the treatment of morbid obesity. However, this operation was also associated with major complications. Consequently, many such procedures were eventually reversed. One of the most serious of these complications was liver failure. For those patients who developed cirrhosis, liver transplantation was one therapeutic alternative. Tacrolimus is one of the primary immunosuppressive agents used in liver transplantation. It is effective to prevent acute rejection episodes, but shows a narrow therapeutic index and can cause nephrotoxicity and neurotoxicity. This report describes the change in tacrolimus absorption that was observed after JIB reversal in a 57-year-old female liver transplant recipient.. Prior to JIB reversal, the mean tacrolimus dose was 7 mg twice daily with a whole-blood tacrolimus concentration ranging from 5.2 to 6.4 ng/mL. There was no appreciable peak in tacrolimus concentration, and the area under the concentration-time curve (AUC) was 10.9 ng/mL/h. After reversal, the daily tacrolimus dose was decreased to 5 mg twice daily, with a now-discernable peak concentration at 3 hours postdose. Furthermore, the AUC increased 90% to 20.7 ng/mL/h.. After JIB reversal, the patient showed higher systemic levels of tacrolimus and required lower steady-state doses. It is therefore imperative that such patients be monitored closely to avoid tacrolimus-related toxicity.

    Topics: Administration, Oral; Female; Humans; Immunosuppressive Agents; Intestinal Absorption; Jejunoileal Bypass; Liver Transplantation; Middle Aged; Obesity, Morbid; Reoperation; Tacrolimus

2005